Mosaic Q2 Call Echoes Phosphate Pain, No Relief Yet

What happened

Mosaic's Q2 earnings call underscored a still-hostile phosphate market, with CEO Bruce Bodine citing unusually high sulfur prices and constrained supply as persistent headwinds. The company reiterated its focus on managing production, costs, and liquidity, a stance consistent with Q1's operating loss and the withdrawal of full-year phosphate guidance. While potash remains the lone earnings bright spot, the call offered no indication that sulfur/ammonia inflation is easing or that phosphate curtailments will end soon. The thesis continues to hinge on a near-term input-cost rollover and Brazil restructuring progress, neither of which has materialized. Investors are left waiting for concrete signs of margin recovery before the stock can re-rate from its deeply discounted valuation.

Implication

With Q2 confirming elevated sulfur and constrained supply, the recovery timeline remains uncertain. Investors should monitor for reinstated phosphate guidance or evidence sulfur prices are rolling over. Until then, MOS trades on potash cost-down potential and balance-sheet strength, but earnings recovery is not imminent.

Thesis delta

No change. The investment case remains a waiting game for phosphate input cost normalization and Brazil restructuring to unlock value. Q2’s commentary reinforces the near-term earnings pressure but does not alter the risk/reward skew, as the stock already prices in deep distress. Re-assessment still depends on sulfur/ammonia relief and management restoring production visibility.